{
    "clinical_study": {
        "@rank": "97725", 
        "arm_group": {
            "arm_group_label": "Filgrastim + ABVD Chemotherapy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Prophylactic use of Filgrastim SD/01 for patients with Hodgkin's lymphoma receiving ABVD\n      chemotherapy."
        }, 
        "brief_title": "Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy", 
        "completion_date": {
            "#text": "March 2005", 
            "@type": "Actual"
        }, 
        "condition": "Hodgkin Disease", 
        "condition_browse": {
            "mesh_term": "Hodgkin Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION:\n\n          -  Previously untreated Hodgkin's disease patients who are scheduled to receive standard\n             ABVD chemo.\n\n          -  Histologically proven diagnosis of Hodgkin's disease of any type.\n\n          -  Bidimensionally measurable disease.\n\n          -  Signed informed consent.\n\n          -  Age >/= 16 yrs.\n\n          -  Adequate bone marrow reserve (ANC>1000/uL, Platelet  >100,000/uL.\n\n          -  LVEF>/=50% by MUGA scan or echocardiogram.\n\n          -  Serum creatinine <2mg/dL; serum bilirubin<2mg/dL.\n\n        EXCLUSION:\n\n          -  HIV positive.\n\n          -  Pregnant women and those of child bearing age who are not using adequate\n             contraception.\n\n          -  Prior chemotherapy.\n\n          -  Severe pulmonary disease including COPD and asthma.\n\n          -  History of prior sensitivity to E.coli derived products."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 31, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00038558", 
            "org_study_id": "ID01-087"
        }, 
        "intervention": [
            {
                "arm_group_label": "Filgrastim + ABVD Chemotherapy", 
                "intervention_name": "Filgrastim SD/01", 
                "intervention_type": "Drug", 
                "other_name": [
                    "G-CSF", 
                    "Neupogen"
                ]
            }, 
            {
                "arm_group_label": "Filgrastim + ABVD Chemotherapy", 
                "intervention_name": "Adriamycin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Doxorubicin Hydrochloride", 
                    "Adriamycin PFS", 
                    "Adriamycin RDF"
                ]
            }, 
            {
                "arm_group_label": "Filgrastim + ABVD Chemotherapy", 
                "intervention_name": "Bleomycin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Bleomycin sulfate", 
                    "Blenoxane", 
                    "BLM"
                ]
            }, 
            {
                "arm_group_label": "Filgrastim + ABVD Chemotherapy", 
                "intervention_name": "Vinblastine", 
                "intervention_type": "Drug", 
                "other_name": "Velban"
            }, 
            {
                "arm_group_label": "Filgrastim + ABVD Chemotherapy", 
                "intervention_name": "DTIC", 
                "intervention_type": "Drug", 
                "other_name": [
                    "DTIC-Dome", 
                    "Dacarbazine"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bleomycin", 
                "Doxorubicin", 
                "Dacarbazine", 
                "Vinblastine", 
                "Lenograstim"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hodgkin's lymphoma", 
            "Dacarbazine", 
            "DTIC", 
            "DTIC-Dome", 
            "Vinblastine", 
            "Velban", 
            "Bleomycin sulfate", 
            "Blenoxane", 
            "BLM", 
            "Doxorubicin Hydrochloride", 
            "Adriamycin", 
            "Filgrastim", 
            "G-CSF", 
            "Neupogen", 
            "Pegfilgrastim", 
            "granulocyte colony-stimulating factor"
        ], 
        "lastchanged_date": "July 27, 2012", 
        "link": {
            "description": "UT MD Anderson Cancer Center website", 
            "url": "http://www.mdanderson.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "UT MD Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prophylactic Use of Filgrastim SD/01 In Patients With Hodgkin's Disease Receiving ABVD Chemotherapy", 
        "overall_official": {
            "affiliation": "UT MD Anderson Cancer Center", 
            "last_name": "Anas Younes, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of Patients with Response to Prophylactic Filgrastim SD/01Chemotherapy", 
            "safety_issue": "No", 
            "time_frame": "Following  ABVD chemotherapy course"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038558"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "M.D. Anderson Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "M.D. Anderson Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }, 
    "geocoordinates": {
        "UT MD Anderson Cancer Center": "29.76 -95.369"
    }
}